Apresoline contains hydralazine, an antihypertensive indicated in the management of high blood pressure and heart failure, and is registered in ten countries across several distinct regions. The brand has a long-established place in cardiovascular practice, and travellers familiar with it from one market may well encounter it — or its active ingredient under another name — elsewhere.
Hydralazine is classified as an antihypertensive and hypotensive agent. Beyond chronic hypertension and congestive heart failure, the registered indications for Apresoline also extend into acute settings, including hypertensive crisis and eclampsia in obstetric care. The structured indication block on this page details each registered use as recognised by national regulators in the markets where Apresoline is sold.
The footprint spans markets as varied as Japan, the United Kingdom, Egypt, Australia, and Canada, alongside Taiwan, New Zealand, Cyprus, Oman, and the United States. Despite this geographic spread, Apresoline is not universally distributed, and a traveller arriving in a country outside this list may not find the same brand on a pharmacy shelf. Hydralazine itself, however, is a long-standing molecule that circulates internationally under generic names and other brand labels.
Other medications in the broader antihypertensive category are available in essentially every regulated market in the world, although they act through different mechanisms and are not interchangeable without medical guidance. A local pharmacist can confirm whether hydralazine — or a clinically appropriate alternative within the antihypertensive class — is available regionally. Because cardiovascular therapy is highly individualised, any decision to begin, change, or substitute Apresoline should be made together with a prescribing healthcare provider rather than at the counter.
No deaths due to acute poisoning have been reported.
Highest known dose survived: adults, 10g orally.
Oral LD50 in rats: 173 and 187 mg/kg.
Signs and symptoms of overdosage include hypotension, tachycardia, head- ache, and generalized skin flushing.
Complications can include myocardial ischemia and subsequent myocardial infarction, cardiac arrhythmia, and profound shock.
There is no specific antidote.
The gastric contents should be evacuated, taking adequate precautions against aspiration and for protection of the airway. An
activated charcoal slurry may be instilled if conditions permit. These manipulations may have to be omitted or carried out after
cardiovascular status has been stabilized, since they might precipitate cardiac arrhythmias or increase the depth of shock.
Support of the cardiovascular system is of primary importance. Shock should be treated with plasma expanders. If possible,
vasopressors should not be given, but if a vasopressor is required, care should be taken not to precipitate or aggravate cardiac
arrhythmia. Tachycardia responds to beta blockers. Digitalization may be necessary, and renal function should be monitored and
supported as required.
No experience has been reported with extracorporeal or peritoneal dialysis.
In a few patients hydralazine may produce a clinical picture simulating systemic lupus erythematosus including glomerulonephritis. In such patients hydralazine should be discontinued unless the benefit-to-risk determination requires continued antihypertensive therapy with this drug. Symptoms and signs usually regress when the drug is discontinued but residua have been detected many years later. Long-term treatment with steroids may be necessary. (See PRECAUTIONS, Laboratory Tests.)
PRECAUTIONSGeneral
Myocardial stimulation produced by Apresoline (hydralazine) can cause anginal attacks and ECG changes of myocardial ischemia. The drug has been implicated in the production of myocardial infarction. It must, therefore, be used with caution in patients with suspected coronary artery disease.
The “hyperdynamic" circulation caused by Apresoline (hydralazine) may accentuate specific cardiovascular inadequacies. For example, Apresoline (hydralazine) may increase pulmonary artery pressure in patients with mitral valvular disease. The drug may reduce the pressor responses to epinephrine. Postural hypotension may result from Apresoline (hydralazine) but is less common than with ganglionic blocking agents. It should be used with caution in patients with cerebral vascular accidents.
In hypertensive patients with normal kidneys who are treated with Apresoline (hydralazine) , there is evidence of increased renal blood flow and a maintenance of glomerular filtration rate. In some instances where control values were below normal, improved renal function has been noted after administration of Apresoline (hydralazine). However, as with any antihypertensive agent, Apresoline (hydralazine) should be used with caution in patients with advanced renal damage.
Peripheral neuritis, evidenced by paresthesia, numbness, and tingling, has been observed. Published evidence suggests an antipyridoxine effect, and that pyridoxine should be added to the regimen if symptoms develop. The Apresoline (hydralazine) tablets (100 mg) contain FD&C Yellow No. 5 (tartrazine), which may cause allergic-type reactions (including bronchial asthma) in certain susceptible individuals. Although the overall incidence of FD&C Yellow No. 5 (tartrazine) sensitivity in the general population is low, it is frequently seen in patients who are also hypersensitive to aspirin.
Information for Patients
Patients should be informed of possible side effects and advised to take the medication regularly and continuously as directed.
Laboratory Tests
Complete blood counts and antinuclear antibody titer determinations are indicated before and periodically during prolonged therapy with hydralazine even though the patient is asymptomatic. These studies are also indicated if the patient develops arthralgia, fever, chest pain, continued malaise, or other unexplained signs or symptoms.
A positive antinuclear antibody titer requires that the physician carefully weigh the implications of the test results against the benefits to be derived from antihypertensive therapy with hydralazine.
Blood dyscrasias, consisting of reduction in hemoglobin and red cell count, leukopenia, agranulocytosis, and purpura, have been reported. If such abnormalities develop, therapy should be discontinued.
Drug/Drug Interactions
MAO inhibitors should be used with caution in patients receiving hydralazine.
When other potent parental antihypertensive drugs, such as diazoxide, are used in combination with hydralazine, patients should be continuously observed for several hours for any excessive fall in blood pressure. Profound hypotensive episodes may occur when diazoxide infection and Apresoline (hydralazine) are used concomitantly.
Drug/Food Interactions
Administration of hydralazine with food results in higher plasma levels.
Carcinogenesis, Mutagenesis, Impairment of Fertility
In a lifetime study in Swiss albino mice, there was a statistically significant increase in the incidence of lung tumors (adenomas and adenocarcinomas) of both male and female mice given hydralazine continuously in their drinking water at a dosage of about 250 mg/kg per day (about 80 times the maximum recommended human dose). In a P-year carcinogenicity study of rats given hydralazine by lavage at dose levels of 15, 30, and 60 mg/kg/day (approximately 5 to 20 times the recommended human daily dosage), microscopic examination of the liver revealed a small, but statistically significant, increase in benign neoplastic nodules in male and female rats from the high-dose group and in female rats from the intermediate-dose group. Benign interstitial cell tumors of the testes were also significantly increased in male rats from the high-dose group. The tumors observed are common in aged rats and a significantly increased incidence was not observed until 18 months of treatment. Hydralazine was shown to be mutagenic in bacterial systems (Gene Mutation and DNA Repair) and in one of two rat and one rabbit hepatocyte in vitro DNA repair studies. Additional in vim and in vitro studies using lymphoma cells, germinal cells, and fibroblasts from mice, bone marrow cells from Chinese hamsters and fibroblasts from human cell lines did not demonstrate any mutagenic potential for hydralazine.
The extent to which these findings indicate a risk to man is uncertain. While long-term clinical observation has not suggested that human cancer is associated with hydralazine use, epidemiologic studies have so far been insufficient to arrive at any conclusions.
Pregnancy Category C
Animal studies indicate that hydralazine is teratogenic in mice at 20 to 30 times the maximum daily human dose of 200 to 300 mg and possibly in rabbits at 10 to 15 times the maximum daily human dose, but that it is nonteratogenic in rats. Teratogenic effects observed were cleft palate and malformations of facial and cranial bones.
There are no adequate and well-controlled studies in pregnant women. Although clinical experience does not include any positive evidence of adverse effects on the human fetus, hydralazine should be used during pregnancy only if the expected benefit justifies the potential risk to the fetus.
Nursing Mothers
Hydralazine has been shown to be excreted in breast milk.
Pediatric Use
Safety and effectiveness in pediatric patients have not been established in controlled clinical trials, although there is experience with the use of Apresoline (hydralazine) in these patients. The usual recommended oral starting dosage is 0.75 mg/kg of body weight daily in four divided doses. Dosage may be increased gradually over the next 3-4 weeks to a maximum of 7.5 mg/kg or 200 mg daily.
Adverse reactions with Apresoline (hydralazine) are usually reversible when dosage is reduced. However, in some cases it may be necessary to discontinue the drug. The following adverse reactions have been observed, but there has not been enough systematic collection of data to support an estimate of their frequency.
CommonHeadache, anorexia, nausea, vomiting, diarrhea, palpitations, tachycardia, angina pectoris.
Less FrequentDigestive: constipation, paralytic ileus.
Cardiovascular: hypotension, paradoxical pressor response, edema.
Respiratory: dyspnea.
Neurologic: peripheral neuritis evidenced by paresthesia, numbness, and tingling, dizziness: tremors; muscle cramps; psychotic reactions characterized by depression, disorientation, or anxiety.
Genitourinary: difficulty in urination.
Hematologic: blood dyscrasias, consisting of reduction in hemoglobin and red cell count, leukopenia, agranulocytosis, purpura, lymphadenopathy; splenomegaly.
Hypersensitive Reactions: rash, urticaria, pruritus, fever, chills, arthralgia, eosinophilia, and, rarely, hepatitis.
Other: nasal congestion, flushing, lacrimation, conjunctivitis.
DRUG INTERACTIONSMAO inhibitors should be used with caution in patients receiving hydralazine.
When other potent parenteral antihypertensive drugs, such as diazoxide, are used in combination with hydralazine, patients should be continuously observed for several hours for any excessive fall in blood pressure. Profound hypotensive episodes may occur when diazoxide injection and Apresoline (hydralazine) are used concomitantly.
Apresoline is prescribed in the management of hypertension and heart failure, including congestive heart failure, and is also used in obstetric and emergency settings such as eclampsia and hypertensive crisis. It belongs to the antihypertensive class of medications. The structured indication section further down this page lists each registered use exactly as recognised in the markets where Apresoline is sold.
Apresoline contains hydralazine, classified as an antihypertensive and hypotensive agent. Hydralazine has been part of cardiovascular practice for decades and continues to circulate internationally under several brand names and as a generic, particularly in markets where the original patent has long expired and multiple manufacturers produce hydralazine-containing products in parallel.
Apresoline is registered in ten countries, distributed across several regions rather than concentrated in one. Examples include Japan, the United Kingdom, Australia, Egypt, Canada, Taiwan, and the United States. If your country is not represented in this list, a local pharmacist can usually confirm whether hydralazine is available in that market under a different brand name or as a generic preparation.
Hydralazine is sold internationally under several brand names and as a generic, especially in markets where the original patent has expired. Other medications within the broader antihypertensive category also exist, although they act through different mechanisms and are not freely interchangeable without medical guidance. To identify a hydralazine-containing product locally, search the active ingredient on Pill2Trip or ask a pharmacist in your country.
Yes. Apresoline is a prescription medication, and antihypertensive therapy in particular is calibrated to a patient's blood pressure profile, cardiac history, concurrent medications, and individual circumstances. This matters especially for travellers and people relocating between countries, where prescription rules, branded packaging, and available generics differ from one regulatory regime to another. Decisions to start, stop, switch, or substitute hydralazine belong with a healthcare provider.
